Vertex announces UK approval for CASGEVY™
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read Details“It’s a distinct honor to make the Houston Business Journal’s Fast 100 list,” said co-founder and president, Gary M. Hutchinson. “Modality Solutions is redefining what it means to be a cold chain engineering firm in the biopharmaceutical industry sector, and we are pleased to make the Houston area our home. The community is vibrant and provides us with an exceptional business environment and talent pool for us to grow our business.”
The Fast 100 has become the hallmark of entrepreneurial success for the Houston area. For 2019, revenue growth was based on companywide revenue from the fiscal year 2016 to the fiscal year 2018. To qualify, companies had to be Houston area-based, privately held, be for-profit, and have earned at least $1 million in revenue in the last fiscal year. Modality Solutions made its first appearance on the Houston Business Journal’s Fast 100 list with reported two-year revenue growth of 56 percent.
According to Editor-in-Chief, Giselle Rodriguez Greenwood in the publication’s Sept. 27-Oct. 3 issue featuring the honorees, “Congratulations to all 2019 Fast 100 and Innovation Award honorees. Your perseverance and hard work are what defines our city.”
To view our formal Fast 100 press release, click here.
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCongratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read DetailsCongratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details